Publication | Open Access

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer

Breast OncologyOncologyMedicinePathologyNeoadjuvant TreatmentBreast CancerPharmacotherapyCancer TreatmentPhase 2PharmacologyRadiation OncologyMolecular Oncology